{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:07:38Z","timestamp":1790842058403,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012707","name":"The Foundation for Assistance to Small Innovative Enterprises in Science and Technology","doi-asserted-by":"crossref","award":["GRNTIS5\/42610"],"award-info":[{"award-number":["GRNTIS5\/42610"]}],"id":[{"id":"10.13039\/501100012707","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012707","name":"The Foundation for Assistance to Small Innovative Enterprises in Science and Technology","doi-asserted-by":"crossref","award":["GRNTIS5\/42610"],"award-info":[{"award-number":["GRNTIS5\/42610"]}],"id":[{"id":"10.13039\/501100012707","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High expectations have been set on gene therapy with an AAV-delivered shortened version of dystrophin (\u00b5Dys) for Duchenne muscular dystrophy (DMD), with several drug candidates currently undergoing clinical trials. Safety concerns with this therapeutic approach include the immune response to introduced dystrophin antigens observed in some DMD patients. Recent reports highlighted microutrophin (\u00b5Utrn) as a less immunogenic functional dystrophin substitute for gene therapy. In the current study, we created a human codon-optimized \u00b5Utrn which was subjected to side-by-side characterization with previously reported mouse and human \u00b5Utrn sequences after rAAV9 intramuscular injections in <jats:italic>mdx<\/jats:italic> mice. Long-term studies with systemic delivery of rAAV9-\u00b5Utrn demonstrated robust transgene expression in muscles, with localization to the sarcolemma, functional improvement of muscle performance, decreased creatine kinase levels, and lower immunogenicity as compared to \u00b5Dys. An extensive toxicity study in wild-type rats did not reveal adverse changes associated with high-dose rAAV9 administration and human codon-optimized \u00b5Utrn overexpression. Furthermore, we verified that muscle-specific promoters MHCK7 and SPc5-12 drive a sufficient level of rAAV9-\u00b5Utrn expression to ameliorate the dystrophic phenotype in <jats:italic>mdx<\/jats:italic> mice. Our results provide ground for taking human codon-optimized \u00b5Utrn combined with muscle-specific promoters into clinical development as safe and efficient gene therapy for DMD.<\/jats:p>","DOI":"10.1038\/s41598-022-04892-x","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:03:22Z","timestamp":1642417402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression"],"prefix":"10.1038","volume":"12","author":[{"given":"Anna V.","family":"Starikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria V.","family":"Skopenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Polikarpova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis A.","family":"Reshetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana G.","family":"Vassilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg A.","family":"Velyaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Shmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina M.","family":"Savchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav O.","family":"Soldatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Egorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryana V.","family":"Bardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"4892_CR1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mus.23810","volume":"48","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. & Lloyd-Puryear, M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 48, 21\u201326 (2013).","journal-title":"Muscle Nerve"},{"key":"4892_CR2","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan, D. Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol. Ther. 26, 2337\u20132356 (2018).","journal-title":"Mol. Ther."},{"key":"4892_CR3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437 (2010).","journal-title":"N. Engl. J. Med."},{"key":"4892_CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0960-8966(98)00052-2","volume":"8","author":"AO Gramolini","year":"1998","unstructured":"Gramolini, A. O. & Jasmin, B. J. Molecular mechanisms and putative signalling events controlling utrophin expression in mammalian skeletal muscle fibres. Neuromuscul. Disord. NMD 8, 351\u2013361 (1998).","journal-title":"Neuromuscul. Disord. NMD"},{"key":"4892_CR5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF02388063","volume":"25","author":"A Clerk","year":"1993","unstructured":"Clerk, A., Morris, G. E., Dubowitz, V., Davies, K. E. & Sewry, C. A. Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. Histochem. J. 25, 554\u2013561 (1993).","journal-title":"Histochem. J."},{"key":"4892_CR6","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley, J. et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4, 1441\u20131444 (1998).","journal-title":"Nat. Med."},{"key":"4892_CR7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0960-8966(01)00220-6","volume":"11","author":"R Fisher","year":"2001","unstructured":"Fisher, R. et al. Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromuscul. Disord. NMD 11, 713\u2013721 (2001).","journal-title":"Neuromuscul. Disord. NMD"},{"key":"4892_CR8","doi-asserted-by":"crossref","first-page":"13856","DOI":"10.1073\/pnas.0405972101","volume":"101","author":"TOB Krag","year":"2004","unstructured":"Krag, T. O. B. et al. Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc. Natl. Acad. Sci. U. S. A. 101, 13856\u201313860 (2004).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"4892_CR9","doi-asserted-by":"crossref","first-page":"e26169","DOI":"10.1371\/journal.pone.0026169","volume":"6","author":"C Moorwood","year":"2011","unstructured":"Moorwood, C. et al. Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PloS One 6, e26169 (2011).","journal-title":"PloS One"},{"key":"4892_CR10","doi-asserted-by":"crossref","first-page":"e19189","DOI":"10.1371\/journal.pone.0019189","volume":"6","author":"JM Tinsley","year":"2011","unstructured":"Tinsley, J. M. et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PloS One 6, e19189 (2011).","journal-title":"PloS One"},{"key":"4892_CR11","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1371\/journal.pone.0000774","volume":"2","author":"E Mattei","year":"2007","unstructured":"Mattei, E. et al. Utrophin up-regulation by an artificial transcription factor in transgenic mice. PloS One 2, e774 (2007).","journal-title":"PloS One"},{"key":"4892_CR12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbadis.2018.01.030","volume":"1864","author":"C Pisani","year":"2018","unstructured":"Pisani, C. et al. Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1172\u20131182 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"4892_CR13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1073\/pnas.1013067108","volume":"108","author":"AR Amenta","year":"2011","unstructured":"Amenta, A. R. et al. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc. Natl. Acad. Sci. U. S. A. 108, 762\u2013767 (2011).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"4892_CR14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/hum.2015.088","volume":"28","author":"M Ito","year":"2017","unstructured":"Ito, M., Ehara, Y., Li, J., Inada, K. & Ohno, K. Protein-anchoring therapy of biglycan for mdx mouse model of Duchenne muscular dystrophy. Hum. Gene Ther. 28, 428\u2013436 (2017).","journal-title":"Hum. Gene Ther."},{"key":"4892_CR15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.gt.3301941","volume":"10","author":"M Cerletti","year":"2003","unstructured":"Cerletti, M. et al. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther. 10, 750\u2013757 (2003).","journal-title":"Gene Ther."},{"key":"4892_CR16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","volume":"8","author":"SQ Harper","year":"2002","unstructured":"Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253\u2013261 (2002).","journal-title":"Nat. Med."},{"key":"4892_CR17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/mt.2008.149","volume":"16","author":"GL Odom","year":"2008","unstructured":"Odom, G. L., Gregorevic, P., Allen, J. M., Finn, E. & Chamberlain, J. S. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic Dystrophin\/Utrophin-deficient mice. Mol. Ther. J. Am. Soc. Gene Ther. 16, 1539\u20131545 (2008).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"4892_CR18","doi-asserted-by":"crossref","first-page":"e1000083","DOI":"10.1371\/journal.pmed.1000083","volume":"6","author":"KJ Sonnemann","year":"2009","unstructured":"Sonnemann, K. J. et al. Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med. 6, e1000083 (2009).","journal-title":"PLoS Med."},{"key":"4892_CR19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2018.10.005","volume":"11","author":"TL Kennedy","year":"2018","unstructured":"Kennedy, T. L. et al. Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2\/mdx mice. Mol. Ther. Methods Clin. Dev. 11, 92\u2013105 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4892_CR20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","volume":"25","author":"Y Song","year":"2019","unstructured":"Song, Y. et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat. Med. 25, 1505\u20131511 (2019).","journal-title":"Nat. Med."},{"key":"4892_CR21","doi-asserted-by":"crossref","first-page":"e1009179","DOI":"10.1371\/journal.pgen.1009179","volume":"16","author":"GB Banks","year":"2020","unstructured":"Banks, G. B., Chamberlain, J. S. & Odom, G. L. Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. PLoS Genet. 16, e1009179 (2020).","journal-title":"PLoS Genet."},{"key":"4892_CR22","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/mt.2008.186","volume":"16","author":"H Foster","year":"2008","unstructured":"Foster, H. et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2\/8 gene transfer. Mol. Ther. J. Am. Soc. Gene Ther. 16, 1825\u20131832 (2008).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"4892_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-61737-982-6_2","volume":"709","author":"T Athanasopoulos","year":"2011","unstructured":"Athanasopoulos, T., Foster, H., Foster, K. & Dickson, G. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy. Methods Mol. Biol. Clifton NJ 709, 21\u201337 (2011).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"4892_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.32607\/actanaturae.11063","volume":"13","author":"VV Skopenkova","year":"2021","unstructured":"Skopenkova, V. V., Egorova, T. V. & Bardina, M. V. Muscle-specific promoters for gene therapy. Acta Naturae 13, 47 (2021).","journal-title":"Acta Naturae"},{"key":"4892_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/clim.2000.4966","volume":"98","author":"MJ Spencer","year":"2001","unstructured":"Spencer, M. J., Montecino-Rodriguez, E., Dorshkind, K. & Tidball, J. G. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol. Orlando Fla 98, 235\u2013243 (2001).","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"4892_CR26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","volume":"22","author":"TR Flotte","year":"2011","unstructured":"Flotte, T. R. et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing \u03b11-antitrypsin: interim results. Hum. Gene Ther. 22, 1239\u20131247 (2011).","journal-title":"Hum. Gene Ther."},{"key":"4892_CR27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ymthe.2020.01.004","volume":"28","author":"G Gernoux","year":"2020","unstructured":"Gernoux, G. et al. Muscle-directed delivery of an AAV1 vector leads to capsid-specific T cell exhaustion in nonhuman primates and humans. Mol. Ther. J. Am. Soc. Gene Ther. 28, 747\u2013757 (2020).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"4892_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.omtm.2017.07.004","volume":"6","author":"R Ferla","year":"2017","unstructured":"Ferla, R. et al. Non-clinical safety and efficacy of an AAV2\/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI. Mol. Ther. Methods Clin. Dev. 6, 143\u2013158 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4892_CR29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","volume":"15","author":"MZ Salva","year":"2007","unstructured":"Salva, M. Z. et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. J. Am. Soc. Gene Ther. 15, 320\u2013329 (2007).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"4892_CR30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/6981","volume":"17","author":"X Li","year":"1999","unstructured":"Li, X., Eastman, E. M., Schwartz, R. J. & Draghia-Akli, R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17, 241\u2013245 (1999).","journal-title":"Nat. Biotechnol."},{"key":"4892_CR31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF02099968","volume":"19","author":"KE Hastings","year":"1983","unstructured":"Hastings, K. E. & Emerson, C. P. Codon usage in muscle genes and liver genes. J. Mol. Evol. 19, 214\u2013218 (1983).","journal-title":"J. Mol. Evol."},{"key":"4892_CR32","unstructured":"Stedman, H. H., Su, L. T. & Mitchell, M. A. Microutrophin and uses thereof. (2010)."},{"key":"4892_CR33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/humc.2015.006","volume":"26","author":"D Duan","year":"2015","unstructured":"Duan, D. Duchenne muscular dystrophy gene therapy in the canine model. Hum. Gene Ther. Clin. Dev. 26, 57 (2015).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"4892_CR34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285\u2013298 (2018).","journal-title":"Hum. Gene Ther."},{"key":"4892_CR35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/mt.2009.254","volume":"18","author":"LR Rodino-Klapac","year":"2010","unstructured":"Rodino-Klapac, L. R. et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther. 18, 109\u2013117 (2010).","journal-title":"Mol. Ther."},{"key":"4892_CR36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","volume":"11","author":"G Ronzitti","year":"2020","unstructured":"Ronzitti, G., Gross, D.-A. & Mingozzi, F. Human immune responses to adeno-associated virus (AAV) vectors. Front. Immunol. 11, 670 (2020).","journal-title":"Front. Immunol."},{"key":"4892_CR37","unstructured":"Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD) |Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd."},{"key":"4892_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneuroim.2003.11.013","volume":"148","author":"L Mesnard-Rouiller","year":"2004","unstructured":"Mesnard-Rouiller, L., Bismuth, J., Wakkach, A., Po\u00eba-Guyon, S. & Berrih-Aknin, S. Thymic myoid cells express high levels of muscle genes. J. Neuroimmunol. 148, 97\u2013105 (2004).","journal-title":"J. Neuroimmunol."},{"key":"4892_CR39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1152\/physiolgenomics.2000.3.3.133","volume":"3","author":"S Ebihara","year":"2000","unstructured":"Ebihara, S. et al. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol. Genomics 3, 133\u2013144 (2000).","journal-title":"Physiol. Genomics"},{"key":"4892_CR40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.omtm.2017.06.006","volume":"6","author":"CH Hakim","year":"2017","unstructured":"Hakim, C. H. et al. A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe DBA\/2J-mdx model of duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 6, 216\u2013230 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4892_CR41","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/gt.2008.104","volume":"15","author":"B Wang","year":"2008","unstructured":"Wang, B. et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther. 15, 1489\u20131499 (2008).","journal-title":"Gene Ther."},{"key":"4892_CR42","doi-asserted-by":"crossref","first-page":"112033","DOI":"10.1016\/j.yexcr.2020.112033","volume":"392","author":"KA Danilov","year":"2020","unstructured":"Danilov, K. A. et al. In vitro assay for the efficacy assessment of AAV vectors expressing microdystrophin. Exp. Cell Res. 392, 112033 (2020).","journal-title":"Exp. Cell Res."},{"key":"4892_CR43","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/mtm.2016.35","volume":"3","author":"P-O Buclez","year":"2016","unstructured":"Buclez, P.-O. et al. Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system. Mol. Ther. Methods Clin. Dev. 3, 16035 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4892_CR44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.gt.3300938","volume":"6","author":"S Zolotukhin","year":"1999","unstructured":"Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973\u2013985 (1999).","journal-title":"Gene Ther."},{"key":"4892_CR45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/hgtb.2011.034","volume":"23","author":"C Aurnhammer","year":"2012","unstructured":"Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18\u201328 (2012).","journal-title":"Hum. Gene Ther. Methods"},{"key":"4892_CR46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4939-7172-5_4","volume":"1641","author":"M Slaoui","year":"2017","unstructured":"Slaoui, M., Bauchet, A.-L. & Fiette, L. Tissue sampling and processing for histopathology evaluation. Methods Mol. Biol. Clifton NJ 1641, 101\u2013114 (2017).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"4892_CR47","doi-asserted-by":"publisher","DOI":"10.3791\/51303","author":"A Aartsma-Rus","year":"2014","unstructured":"Aartsma-Rus, A. & van Putten, M. Assessing functional performance in the mdx mouse model. J. Vis. Exp. JoVE https:\/\/doi.org\/10.3791\/51303 (2014).","journal-title":"J. Vis. Exp. JoVE"},{"key":"4892_CR48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1242\/dmm.037655","volume":"12","author":"TV Egorova","year":"2019","unstructured":"Egorova, T. V. et al. CRISPR\/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene. Dis. Model. Mech. 12, 150 (2019).","journal-title":"Dis. Model. Mech."},{"key":"4892_CR49","doi-asserted-by":"crossref","first-page":"C985","DOI":"10.1152\/ajpcell.00128.2007","volume":"293","author":"S Chan","year":"2007","unstructured":"Chan, S., Head, S. I. & Morley, J. W. Branched fibers in dystrophic mdx muscle are associated with a loss of force following lengthening contractions. Am. J. Physiol. Cell Physiol. 293, C985-992 (2007).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"4892_CR50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1023\/A:1014587918367","volume":"22","author":"C Dellorusso","year":"2001","unstructured":"Dellorusso, C., Crawford, R. W., Chamberlain, J. S. & Brooks, S. V. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. 22, 467\u2013475 (2001).","journal-title":"J. Muscle Res. Cell Motil."},{"key":"4892_CR51","first-page":"4377","volume":"19","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Identification of suitable reference genes for gene expression studies in rat skeletal muscle following sciatic nerve crush injury. Mol. Med. Rep. 19, 4377\u20134387 (2019).","journal-title":"Mol. Med. Rep."},{"key":"4892_CR52","doi-asserted-by":"crossref","first-page":"e0211384","DOI":"10.1371\/journal.pone.0211384","volume":"14","author":"JCW Hildyard","year":"2019","unstructured":"Hildyard, J. C. W., Finch, A. M. & Wells, D. J. Identification of qPCR reference genes suitable for normalizing gene expression in the mdx mouse model of Duchenne muscular dystrophy. PLOS ONE 14, e0211384 (2019).","journal-title":"PLOS ONE"},{"key":"4892_CR53","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1471-2105-9-482","volume":"9","author":"TR Jones","year":"2008","unstructured":"Jones, T. R. et al. Cell profiler analyst: data exploration and analysis software for complex image-based screens. BMC Bioinf. 9, 482 (2008).","journal-title":"BMC Bioinf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-04892-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-04892-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-04892-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:16:24Z","timestamp":1669328184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-04892-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4892"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-04892-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"848"}}